{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:06:18Z","timestamp":1789538778712,"version":"build-2803163510"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Alexion, AstraZeneca Rare Disease to Baylor Medical College for data collection during the course of this study"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurofibromatosis type 1 (NF1) is a genetic condition that affects an estimated 1 in 3000 people worldwide. Between 30% and 50% of patients with NF1 develop symptomatic, inoperable plexiform neurofibromas. To identify the unmet needs and understand the potential value of new treatments, the treatment patterns, healthcare resource utilization (HCRU), and clinical outcomes were evaluated in a real-world cohort of 102 pediatric patients with NF1 and PN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective data were collected from patients diagnosed with NF1 and symptomatic, inoperable PNs from 2000 to 2018 across 3 US sites. Data on clinical characteristics, site visits, treatments, and outcomes were collected through 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with NF1, on average, developed 3.5 symptomatic, inoperable PNs during the study. PN complications included pain (76.5%), disfigurement (45.1%), and motor dysfunction (13.7%). During the study period, which was prior to Food and Drug Administration (FDA) approval of mitogen-activated protein kinase inhibitors for NF1, available treatments attempted to address the symptoms caused by PNs but did not typically slow or prevent their growth. Surgery was performed for 38.1% of study patients. At follow-up of \u226512 months, 62.5% of PNs regrew after surgery. Each year, patients made, on average, 6 visits to an outpatient care center and 1 visit to an oncologist. Nearly all patients (99.0%) received at least 1 diagnostic imaging scan, with 3.4 scans per year on average.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study describes the high burden of HCRU among pediatric patients with NF1-PN prior to FDA approval of pharmacologic therapies for PN and demonstrates the need for effective treatment options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/nop\/npag038","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:26:22Z","timestamp":1781501182000},"page":"1012-1022","source":"Crossref","is-referenced-by-count":0,"title":["Treatment patterns and healthcare resource utilization in pediatric neurofibromatosis type 1-associated symptomatic plexiform neurofibroma in the United States from 2000 to 2019"],"prefix":"10.1093","volume":"13","author":[{"given":"Surya P","family":"Rednam","sequence":"first","affiliation":[{"name":"Texas Children\u2019s Hospital, Baylor College of Medicine , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Dettling","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease , Boston, Massachusetts,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Blackowicz","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease , Boston, Massachusetts,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randolph","family":"de la Rosa Rodriguez","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease , Boston, Massachusetts,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Yang","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. Value and Implementation Outcomes Research, , Rahway, New Jersey,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Ali","sequence":"additional","affiliation":[{"name":"Texas Children\u2019s Hospital, Baylor College of Medicine , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-1820","authenticated-orcid":false,"given":"Julia","family":"Meade","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania, (J.M.)","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"2026091601513317500_npag038-B1","author":"Genetics Home Reference"},{"key":"2026091601513317500_npag038-B2","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s00381-022-05513-8","article-title":"Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA","volume":"38","author":"Yang","year":"2022","journal-title":"Childs Nerv Syst"},{"key":"2026091601513317500_npag038-B3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/AHMT.S303456","article-title":"Natural history and disease burden of neurofibromatosis type 1 with plexiform neurofibromas: a systematic literature review","volume":"12","author":"Copley-Merriman","year":"2021","journal-title":"Adolesc Health Med Ther"},{"key":"2026091601513317500_npag038-B4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1146\/annurev-pathol-052016-100228","article-title":"Dissecting clinical heterogeneity in neurofibromatosis type 1","volume":"12","author":"Monroe","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"2026091601513317500_npag038-B5","doi-asserted-by":"publisher","first-page":"e2663","DOI":"10.1097\/MD.0000000000002663","article-title":"Plexiform neurofibroma: a case report","volume":"95","author":"Tchernev","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2026091601513317500_npag038-B6","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","article-title":"Management of neurofibromatosis type 1-associated plexiform neurofibromas","volume":"24","author":"Fisher","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026091601513317500_npag038-B7","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-0660","article-title":"Health supervision for children with neurofibromatosis type 1","volume":"143","author":"Miller","year":"2019","journal-title":"Pediatrics"},{"key":"2026091601513317500_npag038-B8","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jpeds.2011.04.008","article-title":"Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits","volume":"159","author":"Nguyen","year":"2011","journal-title":"J Pediatr"},{"key":"2026091601513317500_npag038-B9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jpeds.2018.10.019","article-title":"Patient reported outcomes measurement information system and quality of life in neurological disorders measurement system to evaluate quality of life for children and adolescents with neurofibromatosis type 1 associated plexiform neurofibroma","volume":"206","author":"Lai","year":"2019","journal-title":"J Pediatr"},{"key":"2026091601513317500_npag038-B10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12883-019-1338-y","article-title":"Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study","volume":"19","author":"Sanagoo","year":"2019","journal-title":"BMC Neurol"},{"key":"2026091601513317500_npag038-B11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","article-title":"NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight","volume":"68","author":"Dombi","year":"2007","journal-title":"Neurology"},{"key":"2026091601513317500_npag038-B12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1750-1172-7-75","article-title":"Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1","volume":"7","author":"Nguyen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"2026091601513317500_npag038-B13","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/s0022-3476(97)70092-1","article-title":"Prognostic signs in the surgical management of plexiform neurofibroma: the Children\u2019s Hospital of Philadelphia experience, 1974-1994","volume":"131","author":"Needle","year":"1997","journal-title":"J Pediatr"},{"key":"2026091601513317500_npag038-B14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/BPO.0b013e31820cad77","article-title":"Resection of plexiform neurofibromas in children with neurofibromatosis type 1","volume":"31","author":"Canavese","year":"2011","journal-title":"J Pediatr Orthop"},{"key":"2026091601513317500_npag038-B15","author":"US Food and Drug Administration","year":"2024"},{"key":"2026091601513317500_npag038-B16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s11910-001-0012-z","article-title":"Diagnosis and management of neurofibromatosis type 1","volume":"1","author":"Korf","year":"2001","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2026091601513317500_npag038-B17","author":"United States Food and Drug Administration","year":"2020"},{"key":"2026091601513317500_npag038-B18","author":"US Food and Drug Administration","year":"2025"},{"key":"2026091601513317500_npag038-B19","author":"United States Pharmacopeia","year":"2024"},{"key":"2026091601513317500_npag038-B20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/01.bpo.0000217719.10728.39","article-title":"Neurofibromatosis update","volume":"26","author":"Crawford","year":"2006","journal-title":"J Pediatr Orthop"},{"key":"2026091601513317500_npag038-B21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13052-018-0483-z","article-title":"Clinical and molecular characterization of 112 single-center patients with neurofibromatosis type 1","volume":"44","author":"Corsello","year":"2018","journal-title":"Ital J Pediatr"},{"key":"2026091601513317500_npag038-B22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/2374373518786013","article-title":"Impact of chronic pain on patients\u2019 quality of life: a comparative mixed-methods study","volume":"6","author":"Hadi","year":"2019","journal-title":"J Patient Exp"},{"key":"2026091601513317500_npag038-B23","doi-asserted-by":"publisher","first-page":"1253460","DOI":"10.3389\/fpain.2023.1253460","article-title":"Chronic pain: its impact on the quality of life and gender","volume":"4","author":"Pandelani","year":"2023","journal-title":"Front Pain Res (Lausanne)"},{"key":"2026091601513317500_npag038-B24","doi-asserted-by":"publisher","first-page":"13030","DOI":"10.5070\/D3208023523","article-title":"Social impact of the burden of psoriasis: effects on patients and practice","volume":"20","author":"Feldman","year":"2014","journal-title":"Dermatol Online J"},{"key":"2026091601513317500_npag038-B25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/journalofethics.2018.20.4.peer1-1804","article-title":"Facial disfigurement and identity: a review of the literature and implications for facial transplantation","volume":"20","author":"Rifkin","year":"2018","journal-title":"AMA J Ethics"},{"key":"2026091601513317500_npag038-B26","doi-asserted-by":"publisher","first-page":"e13327","DOI":"10.1111\/ecc.13327","article-title":"Stigma in the face of cancer disfigurement: a systematic review and research agenda","volume":"30","author":"Reynolds","year":"2021","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2026091601513317500_npag038-B27","first-page":"633","article-title":"The psychology of scars: a mini-review","volume":"30","author":"Ngaage","year":"2018","journal-title":"Psychiatr Danub"},{"key":"2026091601513317500_npag038-B28","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/03007995.2024.2322698","article-title":"Patient characteristics, treatment patterns, healthcare resource utilization, and costs among patients diagnosed with neurofibromatosis type 1 with and without plexiform neurofibromas in Japan","volume":"40","author":"Yoshida","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"2026091601513317500_npag038-B29","doi-asserted-by":"publisher","first-page":"Cd007938","DOI":"10.1002\/14651858.CD007938.pub4","article-title":"Gabapentin for chronic neuropathic pain in adults","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026091601513317500_npag038-B30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2147\/PHMT.S265690","article-title":"Treatment, resource use and costs among pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas","volume":"11","author":"Yang","year":"2020","journal-title":"Pediatric Health Med Ther"},{"key":"2026091601513317500_npag038-B31","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1046\/j.1365-2133.2000.03543.x","article-title":"Cost evaluation of the medical management of neurofibromatosis 1: a prospective study on 201 patients","volume":"142","author":"Wolkenstein","year":"2000","journal-title":"Br J Dermatol"},{"key":"2026091601513317500_npag038-B32","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1080\/03007995.2021.1940907","article-title":"Characteristics, treatment patterns, healthcare resource use, and costs among pediatric patients diagnosed with neurofibromatosis type 1 and plexiform neurofibromas: a retrospective database analysis of a medicaid population","volume":"37","author":"Yang","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"2026091601513317500_npag038-B33","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jpsychires.2021.06.002","article-title":"Predictors of cognitive, behavioural and academic difficulties in NF1","volume":"140","author":"Geoffray","year":"2021","journal-title":"J Psychiatr Res"},{"key":"2026091601513317500_npag038-B34","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-067016","article-title":"Academic achievement of children with neurofibromatosis type 1","volume":"155","author":"Hou","year":"2025","journal-title":"Pediatrics"}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npag038\/68524550\/npag038.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/13\/5\/1012\/68524550\/npag038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/13\/5\/1012\/68524550\/npag038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:51:40Z","timestamp":1789537900000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/13\/5\/1012\/8707852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,6,13]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npag038","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"value":"2054-2577","type":"print"},{"value":"2054-2585","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,6,13]]}}}